Abciximab and fatal pulmonary hemorrhage

Area of Science:

• Cardiology
• Pharmacology
• Pulmonology

Background:

• Abciximab, a glycoprotein IIb/IIIa receptor antagonist, is widely used during percutaneous coronary intervention for its antiplatelet and antithrombotic properties.
• While effective in improving outcomes, abciximab therapy is associated with bleeding complications.
• Pulmonary hemorrhage is an infrequent but severe and often fatal adverse event linked to abciximab use.

Observation:

• This report details a case of fatal pulmonary hemorrhage in a young woman with acute myocardial infarction and cardiogenic shock.
• The patient received abciximab concurrently with percutaneous coronary intervention.
• Clinical indicators for suspecting diffuse pulmonary hemorrhage include hypoxemia, radiographic infiltrates, and falling hemoglobin levels.

Findings:

• The case highlights pulmonary hemorrhage as a serious, under-recognized complication of abciximab therapy.
• Early recognition of symptoms like hypoxemia and anemia in patients treated with abciximab is critical.
• Potential, though unproven, interventions include bronchoscopic-guided balloon tamponade and iced saline lavage.

Implications:

• Physicians and healthcare professionals must be aware of the risk of pulmonary hemorrhage associated with abciximab.
• Prompt diagnosis and consideration of emerging therapies are warranted for suspected cases.
• Further research is needed to establish the efficacy and survival benefits of interventions for abciximab-induced pulmonary hemorrhage.